Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
Source:http://linkedlifedata.com/resource/pubmed/id/19620495
J. Clin. Oncol.
2009
Aug
20
27
24
3908-15
